Cargando…

Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis

Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Zhigang, Liu, Dezhong, Liu, Chun, Liu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293444/
https://www.ncbi.nlm.nih.gov/pubmed/28151881
http://dx.doi.org/10.1097/MD.0000000000005944
_version_ 1782505082926923776
author Cui, Zhigang
Liu, Dezhong
Liu, Chun
Liu, Gang
author_facet Cui, Zhigang
Liu, Dezhong
Liu, Chun
Liu, Gang
author_sort Cui, Zhigang
collection PubMed
description Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies suitable for further investigation. A meta-analysis was conducted on these studies to investigate the association between serum selenium levels and subsequent prostate cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the overall OR of prostate cancer for the highest versus the lowest levels of serum selenium. We found a pooled OR (95% CI) of 0.76 (0.64, 0.91; P < 0.05). In subgroup analysis, an inverse association between serum selenium levels and prostate cancer risk was found in each of case–control studies, current and former smokers, high-grade cancer cases, advanced cancer cases, and different populations. Such correlations were not found for subgroups containing each of cohort studies, nonsmokers, low-grade cancer cases, and early stage cancer cases. In conclusion, our study suggests an inverse relationship between serum selenium levels and prostate cancer risk. However, further cohort studies and randomized control trials based on non-Western populations are required.
format Online
Article
Text
id pubmed-5293444
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52934442017-02-10 Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis Cui, Zhigang Liu, Dezhong Liu, Chun Liu, Gang Medicine (Baltimore) 7300 Some observational studies have shown that elevated serum selenium levels are associated with reduced prostate cancer risk; however, not all published studies support these results. A literature search of PubMed, Embase, Medline, and the Cochrane Library up until September 2016 identified 17 studies suitable for further investigation. A meta-analysis was conducted on these studies to investigate the association between serum selenium levels and subsequent prostate cancer risk. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the overall OR of prostate cancer for the highest versus the lowest levels of serum selenium. We found a pooled OR (95% CI) of 0.76 (0.64, 0.91; P < 0.05). In subgroup analysis, an inverse association between serum selenium levels and prostate cancer risk was found in each of case–control studies, current and former smokers, high-grade cancer cases, advanced cancer cases, and different populations. Such correlations were not found for subgroups containing each of cohort studies, nonsmokers, low-grade cancer cases, and early stage cancer cases. In conclusion, our study suggests an inverse relationship between serum selenium levels and prostate cancer risk. However, further cohort studies and randomized control trials based on non-Western populations are required. Wolters Kluwer Health 2017-02-03 /pmc/articles/PMC5293444/ /pubmed/28151881 http://dx.doi.org/10.1097/MD.0000000000005944 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 7300
Cui, Zhigang
Liu, Dezhong
Liu, Chun
Liu, Gang
Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
title Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
title_full Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
title_fullStr Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
title_full_unstemmed Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
title_short Serum selenium levels and prostate cancer risk: A MOOSE-compliant meta-analysis
title_sort serum selenium levels and prostate cancer risk: a moose-compliant meta-analysis
topic 7300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293444/
https://www.ncbi.nlm.nih.gov/pubmed/28151881
http://dx.doi.org/10.1097/MD.0000000000005944
work_keys_str_mv AT cuizhigang serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis
AT liudezhong serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis
AT liuchun serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis
AT liugang serumseleniumlevelsandprostatecancerriskamoosecompliantmetaanalysis